HC Wainwright Reiterates Buy Rating on Rapport Therapeutics, Sets $66 Target
HC Wainwright reiterated its Buy rating and $66.00 price target. The target implies 130.8% upside from the October 19 close of $28.60.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.